MA30565B1 - Procede de diagnostic et traitement anticancereux - Google Patents

Procede de diagnostic et traitement anticancereux

Info

Publication number
MA30565B1
MA30565B1 MA31490A MA31490A MA30565B1 MA 30565 B1 MA30565 B1 MA 30565B1 MA 31490 A MA31490 A MA 31490A MA 31490 A MA31490 A MA 31490A MA 30565 B1 MA30565 B1 MA 30565B1
Authority
MA
Morocco
Prior art keywords
diagnostic method
anticancer treatment
mage
gene
specific
Prior art date
Application number
MA31490A
Other languages
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA30565B1 publication Critical patent/MA30565B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des amorces et des sondes spécifiques au gène MAGE-A3 destinées à être utilisées dans de nouveaux procédés et kits de diagnostic. L'invention concerne en outre le traitement immunothérapeutique de populations spécifiques de patients atteints de cancer souffrant de tumeurs exprimant le gène MAGE-A3.
MA31490A 2006-06-21 2008-12-19 Procede de diagnostic et traitement anticancereux MA30565B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method

Publications (1)

Publication Number Publication Date
MA30565B1 true MA30565B1 (fr) 2009-07-01

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31490A MA30565B1 (fr) 2006-06-21 2008-12-19 Procede de diagnostic et traitement anticancereux

Country Status (28)

Country Link
US (1) US8936919B2 (fr)
EP (1) EP2041308B1 (fr)
JP (2) JP2009540812A (fr)
KR (1) KR101455589B1 (fr)
CN (1) CN101506383B (fr)
AU (1) AU2007263019B2 (fr)
BR (1) BRPI0713599A2 (fr)
CA (1) CA2656909A1 (fr)
CO (1) CO6140072A2 (fr)
CY (1) CY1113290T1 (fr)
DK (1) DK2041308T3 (fr)
EA (1) EA016347B1 (fr)
ES (1) ES2389513T3 (fr)
GB (1) GB0612342D0 (fr)
HK (1) HK1127627A1 (fr)
HR (1) HRP20120761T1 (fr)
IL (1) IL195975A (fr)
MA (1) MA30565B1 (fr)
MX (1) MX2008016493A (fr)
MY (1) MY147511A (fr)
NO (1) NO20085290L (fr)
NZ (1) NZ573809A (fr)
PL (1) PL2041308T3 (fr)
PT (1) PT2041308E (fr)
SI (1) SI2041308T1 (fr)
UA (1) UA95956C2 (fr)
WO (1) WO2007147876A2 (fr)
ZA (1) ZA200810695B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
JP5883443B2 (ja) * 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
EP0656788B1 (fr) * 1992-08-07 2006-10-18 Pharmexa Inc. Peptides de liaison de hla, et leurs utilisations
CA2184482A1 (fr) * 1994-03-01 1995-09-08 Etienne De Plaen Determination d'etats cancereux par l'expression de genes mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
DK1659179T3 (da) * 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
JP2005515192A (ja) * 2001-11-29 2005-05-26 ダンドリット バイオテック アクティーゼルスカブ ヒト又は動物において免疫応答を誘導するための医薬組成物
EP1560931B1 (fr) 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
DK1572105T3 (da) * 2002-11-14 2011-10-17 Wayne John Cancer Inst Detektion af mikrometastase af melamoner og brystcancer i paraffinindlejret tumor drænende lymfeknuder ved hjælp af kvantitativ multimaker RT-PCR
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
SI2041308T1 (sl) 2012-10-30
GB0612342D0 (en) 2006-08-02
CA2656909A1 (fr) 2007-12-27
EP2041308A2 (fr) 2009-04-01
CN101506383A (zh) 2009-08-12
WO2007147876A2 (fr) 2007-12-27
AU2007263019A1 (en) 2007-12-27
CN101506383B (zh) 2013-08-28
EA200802356A1 (ru) 2009-06-30
UA95956C2 (uk) 2011-09-26
KR101455589B1 (ko) 2014-10-28
IL195975A (en) 2012-08-30
HK1127627A1 (en) 2009-10-02
JP2013046630A (ja) 2013-03-07
DK2041308T3 (da) 2012-10-08
JP5705191B2 (ja) 2015-04-22
CO6140072A2 (es) 2010-03-19
IL195975A0 (en) 2009-09-01
PT2041308E (pt) 2012-10-09
BRPI0713599A2 (pt) 2012-11-06
KR20090034900A (ko) 2009-04-08
CY1113290T1 (el) 2016-04-13
EP2041308B1 (fr) 2012-07-11
US8936919B2 (en) 2015-01-20
JP2009540812A (ja) 2009-11-26
NO20085290L (no) 2009-01-19
WO2007147876A3 (fr) 2008-05-15
NZ573809A (en) 2011-12-22
MX2008016493A (es) 2009-05-21
ES2389513T3 (es) 2012-10-26
MY147511A (en) 2012-12-31
HRP20120761T1 (hr) 2012-10-31
ZA200810695B (en) 2014-03-26
US20120040341A1 (en) 2012-02-16
PL2041308T3 (pl) 2012-11-30
AU2007263019B2 (en) 2012-11-08
EA016347B1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
Buddingh et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
CA2900022C (fr) Procede de diagnostic non invasif pour diagnostiquer le cancer de la vessie
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EP1934377A4 (fr) Procédés et compositions permettant d'identifier des biomarqueurs utiles au diagnostic et/ou au traitement d'états biologiques
EP2302079A3 (fr) Analyse pour le diagnostic du lupus érythémateux systémique
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
Reed et al. Expression of cellular adhesion molecule ‘OPCML’is down‐regulated in gliomas and other brain tumours
EP3356412B1 (fr) Ciblage de cellules souches de métastase par l'intermédiaire d'un récepteur d'acide gras (cd36)
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
WO2009015050A3 (fr) Profil d'expression génique pour prédire la survie d'une patiente atteinte d'un cancer des ovaires
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
Lamkin et al. C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages
ATE461294T1 (de) Brustkrebsdiagnoseverfahren
Pal et al. Association between ZIP10 gene expression and tumor aggressiveness in renal cell carcinoma
WO2006099543A3 (fr) Methodes d'evaluation de la toxicite induite par des anticorps
Sharif-Zak et al. CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
Belibasakis et al. Gene expression of transcription factor NFATc1 in periodontal diseases
MA30565B1 (fr) Procede de diagnostic et traitement anticancereux
ES2817331T3 (es) Uso del cabazitaxel en el tratamiento del cáncer de próstata
Advani et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
JP6397765B2 (ja) プロテアソーム阻害剤に応答するバイオマーカー
Elhelbawy et al. Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma
Zhou et al. Clinical value and potential target of miR-27a-3p in pulpitis